The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
11th Jul 20187:00 amRNSLicensee Quark Pharmaceuticals Patient Dosed Ph 3
21st Jun 20187:00 amRNSSilence Strengthens Board and Leadership Team
18th Jun 20184:35 pmRNSPrice Monitoring Extension
15th Jun 20187:00 amRNSPresents Data on Lead Programme SLN124 at EHA
4th Jun 201810:15 amRNSSilence Therapeutics Announces Leadership Change
24th Apr 20187:00 amRNSResults of AGM
19th Apr 20185:00 pmRNSAdditional Listing
3rd Apr 20187:00 amRNSLitigation Update (Portugal and US)
26th Mar 20187:00 amRNSSilence to Present at Scientific Conferences
7th Mar 20187:00 amRNSNotice of AGM
6th Mar 20187:00 amRNSPreliminary results year ended 31 December 2017
5th Mar 20187:00 amRNSSilence to present at Cowen Health Care Conference
22nd Feb 20183:40 pmRNSHolding(s) in Company
20th Feb 20187:00 amRNSNotice of Results
15th Feb 20182:27 pmRNSAdditional Listing
2nd Feb 201811:38 amRNSGrant of share options and restricted stock units
2nd Feb 20188:58 amRNSHolding(s) in Company
31st Jan 201811:48 amRNSHolding(s) in Company
22nd Jan 20187:00 amRNSKey European patent granted
8th Jan 20187:00 amRNSPost year end business update
28th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
15th Dec 20174:40 pmRNSSecond Price Monitoring Extn
15th Dec 20174:35 pmRNSPrice Monitoring Extension
14th Dec 20174:35 pmRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSFurther Partial Disposal - Arrowhead common shares
4th Dec 20177:00 amRNSPartial Disposal of Arrowhead common shares
20th Nov 20177:00 amRNSUpdate on litigation matters
14th Nov 20177:00 amRNSCapital Markets Day
3rd Nov 20177:00 amRNSUpdate on Litigation Matters
2nd Nov 20174:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20179:24 amRNSHolding(s) in Company
24th Oct 20173:59 pmRNSHolding(s) in Company
19th Oct 20175:50 pmRNSHolding(s) in Company
18th Oct 20172:31 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSFurther US patents granted
17th Oct 20173:08 pmRNSServing of claim in the UK High Court
16th Oct 20177:00 amRNSAppointment of Non-Executive Chair
11th Oct 20177:00 amRNSKey US patent granted
6th Oct 20172:40 pmRNSHolding(s) in Company
28th Sep 20171:10 pmRNSHolding(s) in Company
27th Sep 20172:39 pmRNSHolding(s) in Company
27th Sep 20179:48 amRNSHolding(s) in Company
26th Sep 201711:48 amRNSHolding(s) in Company
22nd Sep 20174:00 pmRNSHolding in Company
22nd Sep 20173:15 pmRNSHolding in Company
22nd Sep 20172:15 pmRNSHolding in Company
22nd Sep 20172:01 pmRNSHolding in Company
22nd Sep 20172:00 pmRNSHolding in Company
20th Sep 201712:07 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.